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ORIGINAL ARTICLE
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Background: Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery
and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence inevitably occurs
either locally (80%) or distally (20%), driven by cancer clones that are often genomically distinct from those in the primary
tumour. Glioblastoma cells display a characteristic infiltrative phenotype, invading the surrounding tissue and often spreading
across the whole brain. Cancer cells responsible for relapse can reside in two compartments of residual disease that are left
behind after treatment: the infiltrated normal brain parenchyma and the sub-ventricular zone. However, these two sources of
residual disease in glioblastoma are understudied because of the difficulty in sampling these regions during surgery.
Patient and methods: Here, we present the results of whole-exome sequencing of 69 multi-region samples collected using
fluorescence-guided resection from 11 patients, including the infiltrating tumour margin and the sub-ventricular zone for each
patient, as well as matched blood. We used a phylogenomic approach to dissect the spatio-temporal evolution of each tumour
and unveil the relation between residual disease and the main tumour mass. We also analysed two patients with paired
primary-recurrence samples with matched residual disease.
Results: Our results suggest that infiltrative subclones can arise early during tumour growth in a subset of patients. After
treatment, the infiltrative subclones may seed the growth of a recurrent tumour, thus representing the ‘missing link’ between
the primary tumour and recurrent disease.
Conclusions: These results are consistent with recognised clinical phenotypic behaviour and suggest that more specific
therapeutic targeting of cells in the infiltrated brain parenchyma may improve patient’s outcome.
Key words: glioblastoma, tumour margin, sub-ventricular zone, cancer evolution, phylogenetics
Introduction
Glioblastoma (GB) is a lethal brain cancer against which effective
therapeutic options are lacking [1]. The disease is characterised
by variegated clinical phenotypes [2–4] and intra-tumour hetero-
geneity (ITH) [5–7]. The disease aetiology and clinical course
have distinct features compared with other cancers. Unlike other
solid tumours, GB rarely metastasises outside the brain, but it
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invariably recurs, limiting the median survival to approximately
14 months [1]. In approximately 80% of aggressively treated
patients, disease progression/recurrence occurs within 2 cm of
the resection margin. In the remaining patients, even when com-
plete surgical removal of the primary lesion was possible, the tu-
mour recurs distally [6–8] and even drastic hemispherectomy
procedures fail to eradicate the disease [9]. Cancer cells from
these distal recurrent lesions, despite sharing a common ancestor
with the primary tumour, are often genomically distinct [6–8].
Moreover, at diagnosis, GB already displays a characteristic infil-
trative phenotype, invading the surrounding brain tissue and
often diffusely infiltrating the whole brain [10]. We have shown
previously that malignant clones present in the sub-ventricular
zone (SVZ), a known neural stem cell germinal niche, often con-
tain tumour precursor cells [11], a finding that has been recently
corroborated [12]. Indeed, infiltration is ubiquitous in GB, with
cells migrating through diverse regions of the brain microenvir-
onment including white matter tracts [13] and blood vessels [14].
In addition, up to 10% of GB cases present as multifocal disease
at diagnosis [15], a rare occurrence in other solid tumours.
The accumulating clinical and genomic evidence suggests that
infiltration may be a very early event in GB development, so that
no matter how early a cancer is detected, it has already spread to
distal regions of the brain, including the normal brain parenchyma
and the SVZ (Figure 1A). After treatment (Figure 1B), infiltrative
cells in the brain parenchyma and in the SVZ can drive relapse.
Thus, even in the case of optimal surgery and when the tumour
mass has been macroscopically resected, residual disease will
trigger new growth, giving rise to recurrence, either locally or dis-
tally (Figure 1C). We argue that the recent seminal studies carried
out on primary-recurrent-matched GB samples [6–8] point at the
infiltrative population as the ‘missing link’, connecting the primary
and the recurrent malignant clone in the evolution of the disease.
Methods
Patient cohort and samples
Sixty-nine tissue samples were collected from neurosurgical
fluorescence-guided resections carried out on 10 IDH1 wildtype GB
patients and one IDH1 mutant anaplastic astrocytoma patient (see
supplementary Table S1, available at Annals of Oncology online for
clinical information). Between five and nine multiple samples from
the tumour mass (T, at least 1 cm apart), SVZ and infiltrative mar-
gin (M) areas were collected from each patient (Figure 2). Tumour
mass samples were numbered as the surgery progressed and hence
T4 samples tend to be deeper into the resection cavity than T1 sam-
ples. SVZ samples are taken after T4. In the case of the two pri-
mary/recurrence cases, three samples (T, SVZ and M) were taken
during the primary and secondary surgical resections for a total of
six specimens per patient. Thirty 10-lm cryosections were taken
from each frozen tissue for DNA extraction using the DNeasy Blood
& Tissue kit (Qiagen, Hilden, Germany). Patient informed consent
was obtained and tissue collection/storage protocols were compliant
with the UK Human Tissue Act 2004 and approved by the Local
Regional Ethics Committee (LREC ref 04/Q0108/60). No difference
in 5-ALA labelling capacity was observed between patients.
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Figure 1. Residual disease in glioblastoma. (A) At surgery, only the primary tumour mass (red) is removed (in dark grey the resection cavity).
(B) However, infiltrative cells in the normal brain parenchyma (green) and sub-ventricular zone (SVZ) (blue) are left behind. (C) Residual glio-
blastoma cells infiltrated throughout the brain can give rise to relapse, both locally and distally.
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Whole-exome and targeted sequencing
Between 100 and 300 ng of DNA from each of the 69 tumour specimens
and 11 blood samples were used for whole-exome sequencing using the
Agilent SureSelectXT Human All Exon V5 Kit (Agilent Technologies,
Santa Clara, CA, US). Median coverage was 157 (min. 108, max.
187). A custom targeted sequencing panel for 891 single nucleotide var-
iants (SNVs) (covered by a total of 5090 amplicons) identified from the
exome sequencing data was designed using Agilent’s Haloplex technol-
ogy (TES1). In addition, we designed a separate Agilent SureSelect XT2
capture panel to specifically validate 1054 SNVs found in the M and SVZ
samples across all patients (TES2). Both amplicon (TES1) and targeted
capture (TES2) libraries were sequenced on an Illumina HiSeq2500
obtaining a median coverage of 4050 and 1128, respectively, in
reported variants (Figure 3A and supplementary Figure S1, available at
Annals of Oncology online). Copy number alterations per sample are
reported in Figure 3B. See supplementary Material and methods, avail-
able at Annals of Oncology online for details about bioinformatics
analysis.
Results
ITH in the tumour mass and residual disease
We carried out fluorescence-guided multi-region sampling of
different regions from primary tumours (T1, T2, T3, . . .;
Figure 2A) and also collected samples from the infiltrative margin
M (n¼ 11; Figure 2B) and the SVZ (n¼ 15; Figure 2C). The mar-
gin is defined by non-fluorescent tissue beyond the fluorescent
tumour mass. We reported previously that this area appears his-
tologically as normal brain and is composed by only 5%–10% of
tumour cells [16]. The tumour mass and SVZ samples displayed
high tumour content (median 58.5% and 22.1%, respectively).
The SVZ samples are fluorescent and we demonstrated contain
cancer clones [11]. Clinical and follow-up information, as well as
imaging was available (supplementary Table S1, available at
Annals of Oncology online). Samples from the tumour mass and
SVZ from 7/11 patients were common to our previous studies,
for which we had carried out microarray copy number profiling
and gene expression alone [5, 11]. The margin samples are pre-
sented here for the first time.
In the present study, multi-region whole-exome sequencing
(see supplementary Material and methods, available at Annals of
Oncology online) identified extensive ITH at the level of SNVs.
Heterogeneity at the level of SNV putative drivers (from ref. [4])
was evident in 5/11 patients, especially in EGFR, PIK3R1 and
TP53 (Figure 3A and supplementary Figure S1, available at
Annals of Oncology online). Copy number profiles inferred from
the whole-exome sequencing confirmed the heterogeneity levels
reported in previous studies (Figure 3B and supplementary
Figure S2, available at Annals of Oncology online). Copy number
events were highly recurrent, especially EGFR amplification
(SP42, SP54, SP55, A23 and A34), chromosome 10 loss contain-
ing PTEN (all patients), and CDKN2A homozygous deletion
(SP42, SP52, SP55, SP56, SP57 and A44), corroborating the find-
ings from large scale studies [2]. Our custom-targeted panel
TES1 (see supplementary Material and methods, available at
Annals of Oncology online) confirmed the results from exome
sequencing (Figures 3A and supplementary Figure S1, available at
Annals of Oncology online). See supplementary Table S2, available
at Annals of Oncology online for purity estimations,
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Figure 2. Study design: multi-region tumour and residual disease sampling. (A) The large majority of patients present at diagnosis with a
large tumour mass that is positive for 5-ALA fluorescence. In this study, we collected multiple spatially separated regions of the tumour mass
(four to six regions per tumour in nine patients), as well as matched primary-relapse samples in two patients. (B) Extensive infiltration is also
present in the surrounding normal brain but cancer cells are so sparse beyond the resection margin that do not appear fluorescent. Samples
from the non-fluorescent infiltrative margin were collected from 9/11 patients. From paired primary-recurrent patients, we collected
matched margin from the primary tumour and another margin sample from the relapsed neoplasm. (C) In a subset of patients, disease is
also found in the sub-ventricular zone (SVZ), which appears fluorescent and contains malignant clones. We collected one to three samples of
the SVZ from all patients, including matched SVZ in primary and relapsed tumours. Through surgery and chemo-radiation, it is possible to ex-
tensively remove the primary tumour but treatment is unlikely to completely remove the infiltrative disease, nor cancer cells in the SVZ.
Those represent the majority of residual disease in glioblastoma.
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supplementary Table S3, available at Annals of Oncology online
for copy number states and supplementary Data, available at
Annals of Oncology online for VCF files with SNV calls.
Because the infiltrative margin (M) samples consist of scattered
cancer cells in the surrounding normal brain, the purity of those
samples was expectedly low (5%–10%). Purity is a confounding
factor for calling mutations, leading to possible false-negatives
that may impact the phylogenetic analysis [17]. To tackle this
problem, we designed a second targeted sequencing panel (TES2)
specifically to validate whether mutations that were present in all
the other tumour samples were really absent from the infiltrative
areas (indicating the margin or SVZ as an ancestral subclone).
This panel confirmed that several mutations that appeared trun-
cal to the tumour mass (putative truncal) were not present in the
margin sample (Figure 3A and supplementary Figure S1, avail-
able at Annals of Oncology online, TES2 panel). In addition, to
further support our results, we developed a statistical method to
test whether genomic variants in targeted sequencing that are not
found in the margin are likely to be truly absent, rather than being
false negatives (i.e. in the second case, if there is no power to de-
termine with reasonable certainty that the mutation is not
present).
Our test scans mutations that were identified as ‘putatively
truncal’ from the tumour mass samples (T1, T2, . . .). These
Figure 3. Multi-region genomic profiles of glioblastoma residual disease. (A) For four representative patients we report the cancer cell frac-
tions (>80%) for the tumour mass samples and presence/absence of mutation in all the residual disease samples (see supplementary Figure
S1 for all cases, supplementary Table S2 for purity and supplementary data, available at Annals of Oncology online for sub-ventricular zone
(SVZ) calls). Putative SNV driver events are annotated. WES, whole-exome sequencing; TES1, targeted amplicon sequencing panel 1; TES2, tar-
geted exome capture sequencing panel 2; T1. . .4, tumour mass sample; SVZ, sub-ventricular zone; M, margin. (B) Digital copy number altera-
tions are reported for each sample (see supplementary Figure S2 and Table S3, available at Annals of Oncology online for details).
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mutations have high cancer cell fraction (CCF) in all T samples
(Figure 4A, representative example of patient SP52). We rea-
soned that if the cancer subclones in the margin were just infil-
trative cells deriving from the tumour mass—rather than an
early ancestor—then ‘putative truncal’ mutations should also be
found in the margin (‘truly truncal’). However, a failure to
identify these mutations in the margin, despite the very high
depth of sequencing of targeted panels, may occur as a false-
Figure 4. Testing the absence of putative truncal mutations in the infiltrative margin (representative case SP52). (A) We detected single nu-
cleotide variants (SNVs) using joint-sample variant calling from whole-exome sequencing (WES). We selected SNVs that had cancer cell frac-
tion (CCFÞ  0:8 in all tumour mass samples (T1, T2, . . .) and the same CNA status across all T samples. We call these ‘putative truncal’ SNVs.
If cancer cells in M developed from T, then these mutations are ‘truly truncal’ and should be detected also in M. However, calling these muta-
tions in the margin might be confounded by the low purity of margin samples. (B) From read counts of selected SNVs, we train for every
sample a beta-binomial model of expected variant allele frequency (VAF), accounting for tumour purity and copy number status. This model
describes, for each such SNV, the expected number of reads with the variant allele as a function of sample purity (i.e. we can predict how
many mutant reads we expect to find in a sample like M, at purity 5%). (C) We use deep-sequencing data from targeted panels TES1 and
TES2 to identify which putative truncal SNVs were not detected in the margin sample by any assay (missing SNVs). Based on the beta-bino-
mial trained model, we created a statistical test for the null hypothesis that these mutations are truly truncal in the tumour (and hence pre-
sent also in M) but remain undetected in M due to low purity. (D) Based on the expectation and the depth of coverage achieved for each
tested mutation, we can calculate a P-value under the null. Rejecting the null means that we have evidence for the fact that these SNVs are
not truly truncal, and that they are missing in the margin. This provides further evidence that the margin is ancestral to the tumour mass.
The power of the test increases with higher coverage; we used a conservative setting of worst-case purity with p value (1% tumour, 99% nor-
mal) for the test, and corrected it for multiple testing via Bonferroni.
Original article Annals of Oncology
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negative owing to low purity. Similar to previous approaches
[18], our statistical method accounts for the confounding factor
of purity, and tests the null hypothesis that ‘putative truncal’
mutations are present in the margin, but miss to be detected in
the margin. Rejecting the null indicates that these mutations are
unlikely to be present in M.
We first fit a beta-binomial distribution to the set of putative
truncal mutations, separated by copy number state (Figure 4B,
see supplementary Material and methods, available at Annals of
Oncology online for details). This provides the expected variant
allele frequency of a mutation in a high purity sample, such as
T1–4. This model allows calculation of the expected frequency of
a mutant given any purity value, for example the 5% purity of the
margin sample. We then examine the whole-exome and targeted
sequencing data (TES1 and TES2) from margin samples and con-
sider those putative truncal SNVs that were not detected by any
assay (Figure 4C). Given the coverage achieved at the locus of the
missing mutation, and the beta-binomial model trained on puta-
tive truncal SNVs, we can calculate the likelihood of the data
assuming the null is true (i.e. the mutation is truly truncal but 0
mutant reads are found at the locus, for a given purity).
Application of our method to our dataset revealed that a consid-
erable proportion of testable mutations (see supplementary
Material and methods, available at Annals of Oncology online for
details) were unlikely to be present in the margin (P<0.05 using
Bonferroni correction), even when we assumed the margin purity
to be as low as 1% (Figure 4D). These results indicate that these
SNVs are likely to be absent in M, and hence cannot be truncal.
The method is potentially applicable to any genomic dataset to
test true negatives (see supplementary Material and methods and
Figure S3, available at Annals of Oncology online). The results of
the test for all patients are reported in Figure 3A and supplemen-
tary Figure S1, available at Annals of Oncology online, left hand
side of each heatmap. This allowed us to carry out a more reliable
phylogenetic analysis for each patient that included residual dis-
ease in the SVZ and the infiltrative margin M.
Evolutionary trajectories suggest early ancestor
clones within residual disease
Residual disease samples diverged early from the rest of the tu-
mour mass in the majority of patients for which M samples were
available, with particular evidence for SP49, SP52, SP57, A44,
SP28 for which we could apply our test (Figure 5, testable muta-
tions that did not pass our test were excluded from the phyl-
ogeny). Importantly, residual disease was also found at
recurrence, demonstrating the presence of a reservoir of cancer
cells in the infiltrative margin at relapse (patients A23 and SP28).
In case A23, the primary tumour mass appeared to have origi-
nated from earlier cancer cell lineages located in the margin M
and SVZ collected at primary resection. However, at the time of
relapse, whereas both T and SVZ appear to have acquired add-
itional new mutations (long branch), the ‘M recurrence’ lineage
has remained similar to the primary tumour. A comparable pat-
tern is observed in SP28 where ‘M recurrence’ also shows as an
early residual clone present at relapse. Hence, early ancestral
clones are present both at primary and recurrence and are not
generally resected. We do acknowledge that the bulk tumour
mass at relapse can also be driven by incomplete resection of the
primary tumour due to the neoplastic tissue extending to vital
parts of the brain that cannot be removed. We note that A23 and
SP28 were local recurrences and more residual disease samples
from distal recurrent tumours will need to be collected in the
future.
As a whole, this analysis indicates that subclones present in M
may arise early during tumour growth. Moreover, in 6/11
patients, the SVZ appeared also as an early ancestor, as we previ-
ously reported [11] and as recently confirmed [12]. See supple-
mentary Figure S4, available at Annals of Oncology online for
bootstrapping values. We do acknowledge however that in those
branches some mutations may be missing due to limits of detect-
ability. To validate further these results, we also carried out
single-allele methylation molecular clock analysis [19] on the
same samples for a subset of patients, in particularly those where
we had primary-recurrence pairs (supplementary Figure S5,
available at Annals of Oncology online). Methylation molecular
clock haplotyping is a single-molecule approach that allows read-
ing the status of single CpGs in CpG island from the same DNA
molecule. We have shown that some of these CpG island loci can
be used for phylogenetic reconstruction, both colorectal cancer
and GB [11, 19]. Importantly, because this assay is ‘single-mol-
ecule’, alleles that come from non-proliferative normal cells (e.g.
normal contamination from neurons in the margin samples) can
be discarded because of their low methylation status. Therefore,
this analysis does not suffer from the problems of tumour purity
of the exome analysis (see supplementary Material and methods,
available at Annals of Oncology online). Eliminating the methyla-
tion haplotypes coming from non-cancer cells allows recon-
structing the tumour phylogeny orthogonally with respect to the
exome trees. The results strikingly confirmed the structure of the
phylogenetic trees inferred from exome sequencing, thus corrob-
orating the results in Figure 5.
Interestingly, histopathology reports (pre WHO 2016 revision)
are congruent with these phylogenetic data in multiple cases, for
example SP49 GB with low-grade areas, SP52 and SP28 GB with
oligodendroglial component. Together these data indicate a less
aggressively proliferative phenotype at early stages of the evolu-
tion of the malignancy. After the primary tumour has been
treated with radio- and chemotherapy, the quiescent residual
subclones may trigger new growth and further clonal evolution,
producing the divergence that has been observed by us and others
between primary and recurrent samples in GB. This interpret-
ation of the data is consistent with an early onset of tumour cell
infiltration. Residual ancestral disease present in the SVZ and in
the infiltrative margin is the source of the inevitable relapse that
occurs in GB patients. This model is also consistent with the
high incidence of multifocal lesions and the accumulating evi-
dence of evolutionary divergence that is emerging from genomic
data [6, 7].
Discussion
A key to understanding cancer is not just exposing ITH, the nat-
ural process that underlines clonal evolution, but also to under-
stand such heterogeneity in a way that is clinically relevant and
therapeutically tractable. An important aspect of genomic ITH is
that it embeds the evolutionary history of the tumour, a
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fundamental biological element that cannot be directly measured
in humans. Nevertheless, inferring and understanding that his-
tory may be critical in developing a rationale for combinatorial
therapeutics [20].
Specifically, in this study, we leveraged the spatio-temporal de-
composition of the clonal architecture of the tumour to under-
stand the link between subclones in the main tumour mass and in
residual disease left behind in the surrounding brain parenchyma
and SVZ following surgery. This residual disease is a key factor
contributing to GB treatment failure because of resistance to ra-
diation and alkylating chemotherapy coupled with an inherent
ability to seed re-growth. Therefore, the main message of this
study is that residual disease and not just the main tumour mass
[5–8, 21, 22] must be investigated in depth from the point of view
Figure 5. Phylogenetic reconstruction indicates residual disease subclones may arise early. Phylogenetic trees built with whole-exome
sequencing (WES) data and excluding mutations that do not pass our test show the infiltrative margin sample at the top of the phylogeny,
suggesting it contains cancer clones that occur early during tumour growth. In 6/11 samples the sub-ventricular zone (SVZ) appears as an
early subclone as well. Often the phylogeny recapitulates the spatial structure of the tumour, where T1, T2, . . . T4 samples are taken in this
order as the tumour resection extends deeper into the brain. Matched samples from M and SVZ in paired primary-relapse cases A23 and
SP28 show the role of residual disease in the development of glioblastoma recurrence.
Original article Annals of Oncology
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of tumour evolution if we are to understand how treatment-
resistant disease develops. We acknowledge that to study the
mechanisms that link residual disease to tumour relapse, add-
itional analysis is needed, especially of primary-recurrence pairs
from distal relapses where also SVZ and M would be collected.
However, this remains a technical and ethical challenge.
This observation presents a challenge to the GB research com-
munity to develop the tools and strategies needed to collect and ro-
bustly analyse difficult samples from residual disease areas in
prospective cohorts. Due to the limited number of patients in this
study, additional analyses on larger cohorts are necessary to valid-
ate these findings. We acknowledge that analysing sparse cancer
cells in the margin remains challenging, even with the most
advanced sequencing and bioinformatics approaches currently
available. Further work is also needed to improve purification of
margin samples, which is not currently possible due to lack of reli-
able markers to sort GB cells. Therefore, new efforts of collecting
infiltrative cells that lay distant from the main tumour mass will be
needed to study residual disease with more accuracy. To do this,
post-mortem efforts such as the PEACE study (Postohumous
Evaluation of Advanced Cancer Environment) are likely to play a
key role in revealing the biology of infiltrative disease in GB.
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